Moderna Therapeutics, a high-profile private biotech with scores of preclinical projects, is finally moving toward human trials, recruiting one of the world's largest CROs to help get its much-hyped pipeline moving.
PPD, rumored to be up for sale, spun out its wholly owned biotech company into a stand-alone entity, a move the CRO said will maximize shareholder value.
The private equity owners of CRO giant PPD are looking to either sell the company or take it public, according to Reuters, moves that would follow a trend in the pharma contracting industry.
PPD hired a general manager to help grow its Japan-focused joint venture with Shin Nippon Biomedical Laboratories, snagging a Parexel International veteran as it works to expand its presence in a growing market for clinical development services.
Privately held CRO PPD scored two federal contracts tasking it with helping to improve health outcomes for active-duty soldiers and aiding with the government's stockpile of flu vaccines.
PPD has reached out to clinical trial software provider Cisys LifeSciences to get its hands on technology the company believes can improve the process by which investigators examine and adjudicate safety events.
Startup Clinical Ink said that it's in the midst of a pilot clinical study that incorporates medical device data that's collected through a smartphone app with biopharma Novartis and contract research organization PPD. The trial incorporates medical device connectivity that's provided by Clinical Ink and powered by Qualcomm's 2net Mobile Platform.
PPD, angling to stand out among CROs running pediatric trials, has cemented a network of 8 global sites to accelerate the process of starting studies on kids.
As regulators and payers place increasing importance on real-world data, CRO PPD is working to expand its reach in the field, joining forces with a division of insurance giant Anthem.
PPD has opened a new central lab facility in Shanghai, expanding its testing services into China as it stretches out around the globe.